A Pilot Study Evaluating a Novel Magneto-Fluidic System for Ultra-High Throughput Detection of Circulating Tumor Cells in Patients with Metastatic and Loco-regional Urothelial Bladder Cancer IUSCC-0552

Investigating a Blood Test for Bladder Cancer Detection

Recruiting
18 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to determine if cancer cells in blood can be reliably detected in bladder cancer patients using a new blood test known as a "liquid biopsy."

Detailed description of study

The purpose of this study is to test and optimize this magneto-fluidic system we have developed to capture circulating tumor cells from samples of patients with advanced urothelial bladder cancer, and potentially applu this system to an earlier clinical stage cohort to predict advanced pathology.

Participants will not be paid for their participation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Metastatic and Loco-regional Urothelial Bladder Cancer ,Metastatic urothelial Bladder Cancer ,Loco-regional Urothelial Bladder Cancer ,Urothelial Bladder Cancer ,bladder cancer,cancer,oncology
  • Age: 18 years - 100 years
  • Gender: All

Inclusion Criteria
Patients must have histologically confirmed advanced urothelial bladder cancer, specifically metastatic or muscle invasive disease
Previously untreated patients and patients with prior therapies will be allowed as long as therapy was give > or = 3 weeks prior to blood collection

Updated on 19 Feb 2024. Study ID: 1601654610

This study investigates a blood test called a "liquid biopsy" to find cancer cells in the blood of bladder cancer patients. Bladder cancer is a disease where cells in the bladder grow uncontrollably. This study aims to see if the test can reliably detect these cancer cells.

The study uses a special system called a magneto-fluidic system to capture circulating tumor cells from blood samples. This system is being tested and improved to see if it can work well for patients with advanced bladder cancer and might be used for patients at earlier stages.

  • Who can participate: Participants must have advanced urothelial bladder cancer, either metastatic or muscle invasive. Both untreated patients and those who had treatment more than 3 weeks before blood collection can join.
  • Study details: Participants will have their blood tested using the investigational liquid biopsy to detect cancer cells. Blood samples will be collected once every two weeks over a period of two months. The test uses a magneto-fluidic system to capture circulating tumor cells from the blood. Participants may also undergo additional imaging procedures as part of the study.

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Race
Ethnicity
Other language

Default Content Message Here